BREAKING NEWS
Source: Medical News - Biden-Alzheimer's Disease  Sep 19, 2022  7 days ago
Biden Announces That The COVID-19 Pandemic Is Over! Study Shows COVID-19 Increases The Risk Of Alzheimer In Older Adults By Between 50 to 80 Percent!
1943 Shares
facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
Biden Announces That The COVID-19 Pandemic Is Over! Study Shows COVID-19 Increases The Risk Of Alzheimer In Older Adults By Between 50 to 80 Percent!
Source: Medical News - Biden-Alzheimer's Disease  Sep 19, 2022  7 days ago
Its hilarious that in the last few hours, Biden had announced during a interview on CBS network’s Sixty Minutes that the COVID-19 pandemic is over!
https://twitter.com/60Minutes/status/1571652540592050176
 


Americans are really going heading for a mess in the coming fall and winter season.
 
Already despite attempts by the Biden administration to conceal the real COVID-19 situation in the United States, death rates and hospitalizations are rising and increasing excess deaths are another worrying factor.
https://www.thailandmedical.news/news/covid-19-surge-starting-in-u-s-despite-coverups-29-states-report-a-total-of-98500-new-infections-and-832-deaths-in-last-24-hours
 
The debut of newer BA.2.75 sub-lineages and BF variants and their increasing spread in coming weeks spells a catastrophe in the making.
https://www.thailandmedical.news/news/idiots-at-who-spreading-misinformation-again-and-claiming-covid-19-pandemic-end-is-near-and-claims-infections-rates-declining
 
Even the new boosters being rolled out despite having been tested on only eight mice, are not going to be of any help when dealing with these variants as emerging preliminary study data show that even infections with the previous BA.5 variant accords no protection against these newer sub-lineages. The last standing monoclonal drug bebtelovimab is also showing reduced or no efficacy against the new sub-lineages and none of the existing antivirals approved by the U.S. FDA are going to have any effect against these new sub-lineages!

Even wastewater surveillance is showing that the COVID-19 crisis is far from over in the United States let alone elsewhere in the world.
https://twitter.com/DataDrivenMD/status/1571718831063859204/photo/1

Considering that Biden had contracted the SARS-CoV-2 virus on more than two occasions despite being vaccinated and boostered, Americans should forgive him for his incompetency as a new study has revealed that SARS-CoV-2 infections increases the risk of older adults such as him developing Alzheimer by almost 50 to 80 percent!
 
The study was conducted by researchers from Case Western Reserve University School of Medicine, Ohio-USA, the National Institutes of Health, Maryland-USA and the Center for Clinical Informatics Research and Education, The Metro Health System, Ohio-USA.
 
An infectious etiology of Alzheimer’s disease has been postulated for decades and it remains unknown whether SARS-CoV-2 viral infection is associated with increased risk for Alzheimer’s disease.
The study team conducted a retrospective cohort study of 6,245,282 older adults (age ≥65 years) who had medical encounters between 2/2020–5/2021.
 
The study findings showed that individuals with COVID-19 were at significantly increased risk for new diagnosis of Alzheimer’s disease within 360 days after the initial COVID-19 diagnosis (hazard ratio or HR:1.69, 95% CI: 1.53–1.72), especially in people age ≥85 years and in women.
 
The study findings call for research to understand the underlying mechanisms and for continuous surveillance of long-term impacts of COVID-19 on Alzheimer’s disease.
 
The study findings were published in the peer reviewed Journal of Alzheimer’s Disease. https://content.iospress.com/articles/journal-of-alzheimers-disease/jad220717
 
In the past, it had already been suggested that viral infections may lead to Alzheimer’s Disease (AD) development; however, it is not clear whether SARS-CoV-2 infections can increase the risk for AD.
 
To date, the enhanced risk for SARS-CoV-2 infections among AD patients and the long-term neurologic sequela of coronavirus disease 2019 (COVID-19) (partly representing inflammation-associated changes, which are critical in AD neurological pathophysiology) are indicative of a two-way relationship between SARS-CoV-2 infections and AD.
 
The study team previously showed a high risk of breakthrough SARS-CoV-2 infections among fully vaccinated AD patients.
https://pubmed.ncbi.nlm.nih.gov/33559975/
 
The study team in the current research, examined the risk of new-onset AD among SARS-CoV-2-positive patients in a retrospective cohort study.
 
The research comprised 6,245,282 adults aged ≥ 65 with no prior AD diagnosis. Data were obtained from de-identified EHRs (electronic health records) of more than 95 million SARS-CoV-2-positive patients of outpatient and inpatient visits from healthcare organizations (n=68) across 50 states of the United States (US) covering different geographical, race, age, insurance, and income groups.
 
The research participants were classified into two groups: (i) the SARS-CoV-2-positive group comprising 410,748 individuals who acquired SARS-CoV-2 infections between 2 February 2020 and 30 May 2021; (ii) the SARS-CoV-2-negative group comprising 5,834,534 individuals with no SARS-CoV-2 exposure but had sought medical care from healthcare organizations between 2 February 2020 and 30 May 2021 for non-COVID-19 reasons.
 
Alzheimer’s Disease (AD) and SARS-CoV-2 infection status were based on the ICD-10 (international classification of diseases) codes and laboratory-based analyses. The risk of new-onset AD was examined for the two groups stratified by race (Hispanics, Whites, and Blacks, Whites) and age (65 to 74 years, 75 to 84 years, and ≥85 years).
 
Detailed propensity score matching (PSM) was performed in a 1:1 ratio for demographical parameters and adverse socioeconomic health determinants such as educational difficulties, occupational exposures, social, physical, or psychosocial environments, and factors known to increase AD risk. The team used the Kaplan-Meier estimator and Cox’s proportional modeling to analyze and calculate hazard ratios (HRs).
 
Upon PSM, the emerging data showed that the average age of individuals in both study groups was 74 years, most of whom were females (54%). The average proportions of Blacks, Whites, and Hispanics were 10%, 75%, and 6.7%, respectively, and adverse socioeconomic and psychosocial circumstances were reported for 13% of the sample population.
 
The study team noted that comorbid conditions such as hypertension, obesity, type II diabetes, depression, hearing loss, traumatic brain injury, tobacco smoking, and heavy alcohol consumption were prevalent among 60%, 23%, 30%, 22%, 5.8%, 3.1%,11%, and 3.8% of the sample population, respectively.
 
Before propensity score matching (PSM), the risks of new-onset AD among SARS-CoV-2-positive and SARS-CoV-2-negative individuals were 0.7% and 0.4%, respectively. Post PSM, the risk increased among SARS-CoV-2-positive individuals compared to SARS-CoV-2-negative individuals (HR: 1.7).

HR values for the risk of new-onset AD among COVID-19 patients aged 65 to 74 years, 75 to 84 years, and ≥85 years were 1.7, 1.6, and 1.7, respectively. HR values for the risk among females (HR 1.8) were greater than those for males (HR 1.5). HR values for the risk among Blacks, Whites, and Hispanics were 1.6, 1.6, and 1.3, respectively.
 
Corresponding author, Dr Rong Xu from the Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University told Thailand Medical News, “The study data showed that the risk was highest among adults aged ≥ 85 years (HR 1.9) and among females (HR: 1.8).”
 
The study team also concluded that SARS-CoV-2-positive female adults aged ≥ 85 years were at a significantly higher risk for new-onset AD within 360 days of SARS-CoV-2 infection diagnosis.
 
The study team noted that future studies are required with data validation from multiple sources and longer follow-up periods to elucidate the mechanisms of and for continued surveillance of the impact of SARS-CoV-2 infections on AD.
 
The team also noted that the study limitations include the retrospective and observational nature of the study that could introduce potential biases and AD diagnosis inaccuracy, which may not have affected the relative risk analyses considerably since both groups were formed from the same dataset.
 
In the meanwhile, Americans should by now realized that they are on their own in the coming fall and winter season to deal with the new COVID-19 surges.
 
For the latest COVID-19 News And Updates, keep on logging to Thailand Medical News.
 

MOST READ

Aug 13, 2020  2 years ago
Source: Supplements For COVID-19
Feb 05, 2020  3 years ago
Source : Thailand Medical news